SUMGEN BIOTECH
Jianjian Biotechnology is an antibody drug developer, specializing in the development of therapeutic antibody drugs and the application of antibodies in immunotherapy and immunodiagnosis. Based on CD&MD innovative antibody research and development technology, it has developed products such as tumor immunotherapy antibody drugs and CART antibodies. .
SUMGEN BIOTECH
Industry:
Biotechnology Clinical Trials Health Care Medical
Founded:
2015-01-01
Address:
Hangzhou, Zhejiang, China
Country:
China
Website Url:
http://www.sumgenbio.com
Total Employee:
101+
Status:
Active
Total Funding:
270 M CNY
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta SPF SSL By Default Mobile Non Scaleable Content HSTS Nginx Alibaba Tencent QQ Mail TrustAsia
Similar Organizations
Bainuo Doctors(Shenzhen Bainuo Mingjihui Network Technology Co)
Bainuo Doctors is a Healthcare Start up Based in Shenzhen.
Gracell Biotechnologies
Gracell Biotechnologies is a developer of cancer immune therapy designed to treat cancer.
Hangzhou Just Biotherapeutics (Just China)
Hangzhou Just Biotherapeutics is a comprehensive high-tech design company.
Kexin Health Industry Development
A Healthcare Company based in Changsha,China.
Qihan Biotech
Qihan Biotech is a gene-editing organ transplantation technology developer.
Ringpai National Chain Veterinary Hospital
Tianjin Based is a Healthcare Start Up based in Tianjin.
SA Biotech
SA Biotech is a Healthcare company.
Themis Bioscience
Themis Bioscience is a start-up biotechnology company.
Viva Biotech
Viva Biotech is a Healthcare Start Up Based In Shanghai.
Yuyi Technology
Yuyi Technology is a hydraulic parts manufacturer.
Current Employees Featured
Founder
Investors List
Hankang Capital
Hankang Capital investment in Series B - Sumgen Biotech
China Biotech
China Biotech investment in Series B - Sumgen Biotech
ZSVC
ZSVC investment in Series B - Sumgen Biotech
Addor Capital
Addor Capital investment in Series B - Sumgen Biotech
Baopu Asset Management
Baopu Asset Management investment in Series B - Sumgen Biotech
JC Capital
JC Capital investment in Series B - Sumgen Biotech
Sinopharm Capital
Sinopharm Capital investment in Series B - Sumgen Biotech
Addor Capital
Addor Capital investment in Series B - Sumgen Biotech
Bank of Communications
Bank of Communications investment in Series B - Sumgen Biotech
Shanghai Haoshuo Investment
Shanghai Haoshuo Investment investment in Series B - Sumgen Biotech
Official Site Inspections
http://www.sumgenbio.com
- Host name: 47.95.33.42
- IP address: 47.95.33.42
- Location: Hangzhou China
- Latitude: 30.294
- Longitude: 120.1619
- Timezone: Asia/Shanghai
More informations about "Sumgen Biotech"
尚健生物 - sumgenbio.com
Hangzhou Sumgen Biotech Co., Ltd. (hereinafter referred to as “Sumgen” or the “company”) is a biotechnology company dedicated to advancing scientific innovation in the field of antibody …See details»
尚健生物 - sumgenbio.com
Beijing R&D Center, Sumgen Monoclonal Antibody (Beijing) Biotech Co., Ltd. Officially established.See details»
Sumgen Biotech - Crunchbase Company Profile & Funding
Sumgen Biotech is a Healthcare Start Up Based in Hangzhou.See details»
Sumgen Biotech Company Profile | Management and Employees …
Find contact information for Sumgen Biotech. Learn about their Research & Development, Business Services market share, competitors, and Sumgen Biotech's email format.See details»
SUMGEN - Products, Competitors, Financials, Employees, …
Sep 14, 2019 SUMGEN specializes in the development of monoclonal antibody therapies within the biopharmaceutical industry. The company's main offerings include research and …See details»
Sumgen Company Profile 2024: Valuation, Funding & Investors
Information on valuation, funding, cap tables, investors, and executives for Sumgen. Use the PitchBook Platform to explore the full profile.See details»
Sumgen Biotech - Overview, News & Competitors | ZoomInfo.com
View Sumgen Biotech (www.sumgenbio.com) location in 浙江, China , revenue, industry and description. Find related and similar companies as well as employees by title and much more.See details»
Hangzhou Shangjian Biotechnology Co., Ltd.
了解Hangzhou Shangjian Biotechnology Co., Ltd. (杭州尚健生物技术有限公司)公司的药物管线，治疗领域，技术平台，以及它的19项临床试验, 1篇新闻和2篇文献，疾病领域:肿瘤，血液及 …See details»
尚健生物-动脉网 - vbdata.cn
Dec 30, 2021 杭州尚健生物技术有限公司（以下简称“尚健生物”或“公司”），是一家创新驱动型生物制药企业，致力于创新生物药开发与商业化。公司由原军事医学科学院青年科学家、国家“ …See details»
尚健生物 - sumgenbio.com
Clinical Trial Application of Sumgen Biotech's First-in-class Same-Target ADC Drug SG2918 Accepted by NMPA On July 31, 2023, Hangzhou Sumgen Biotech Co., Ltd. (hereinafter …See details»
Sumgen Biotech - Crunchbase
Sumgen Biotech is a Healthcare Start Up Based in Hangzhou.See details»
Sumgen Biotech - Funding, Financials, Valuation & Investors
In funding over 4 rounds. Their latest funding was raised on Dec 7, 2021 from a Series B round. Sumgen Biotech is funded by 14 investors. Hankang Capital and China Biotech are the most …See details»
Sumgen - VentureRadar
Initium Therapeutics is focused on developing novel therapies for cancer, autoimmune diseases, and fibrosis. Our targeted approach is based on mechanistic understanding of the pathways …See details»
Chime Biologics Enters into a Strategic Cooperation Agreement …
Sep 24, 2021 Chime Biologics Enters into a Strategic Cooperation Agreement with Sumgen Biotech Wuhan, China, September 24, 2021 – Chime Biologics, a leading CDMO that enables …See details»
尚健生物 - sumgenbio.com
On September 28th, Hangzhou Sumgen Biotechnology Co., Ltd. (hereinafter referred to as "Sumgen Biotech") announced that the first subject in the Phase I clinical trial of their …See details»
Sumgen Biotech Closes ￥220M Series B financing - vbdata.cn
Sep 27, 2020 According to PEdaily.cn, Sumgen Biotech has completed a Series B funding round worth 220 million yuan, led by Addor Capi...See details»
Chime Biologics Enters into a Strategic Cooperation Agreement …
鼎康生物与尚健生物签订战略合作协议 【2021年9月24日，武汉】杭州尚健生物技术有限公司（Sumgen Biotech，以下简称“尚健生物”），一家 致力于恶性肿瘤等重大疾病的创新抗体药物 …See details»
尚健生物 - sumgenbio.com
On July 31, 2023, Hangzhou Sumgen Biotech Co., Ltd. (hereinafter referred to as "Sumgen Biotech") announced that the clinical trial application for its independently developed first …See details»
尚健生物 - sumgenbio.com
Hangzhou Sumgen Biotech Co., Ltd. (hereinafter referred to as Sumgen) announced today that its self-developed Chinese clinical study of anti-CD38 monoclonal antibody SG301 injection …See details»